Hepatitis C in 2007: «The progress. One can do better...»;L'hépatite C en 2007 «Des progrès. Peut-on mieux faire...»

Gastroenterologie Clinique et Biologique

Volumn 31, Issue 8-9 C3, 2007, Pages

  Marcellin, Patrick ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE COURSE; EDITORIAL; EDUCATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; LIVER TRANSPLANTATION; MORTALITY; PREVALENCE;

EID: 35848970105     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0399-8320(07)92556-7     Document Type: Editorial

References (37)

1. National Institutes of Health Consensus Development Conference Management of Hepatitis C. Hepatology 2002;36:S3-S20.
2. EASL International Consensus Conference on Hepatitis C. Consensus Statement. J Hepatol 1999;30:956-61.
3. Consensus conference. Treatment of Hepatitis C. Guidelines. Gastroenterol Clin Biol 2002;26:B312-B20.
4. Alter MJ. Epidemiology of hepatitis C in the West. Seminars in liver disease 1995;15:5-14.
5. Naoumov N. Hepatitis C virus infection in Eastern Europe. J Hepatol 1999;31:S84-S7.
6. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002;36:S30-S4.
7. Marcellin P, Pequignot F, Delaroque-Astagneau E, Ganne N, Hillon P, Bovet M, et al. Evidence for high rates of HCV and HBV related mortality in France: a large-scale national survey. J Hepatol 2006;44:S174.
8. Poynard T, Bedossa P, Opolon P for the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32.
9. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-50.
10. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002;36:S47-S56.
11. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, et al. Influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long term retrospective cohort study. Hepatology 2001;34:1193-9.
12. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006;55:123-30.
13. Marcellin P, Lévy S, Erlinger S. Therapy of hepatitis C:patients with normal aminotransferase levels. Hepatology 1997;26:S33-S7.
14. Martinot-Peignoux M, Boyer N, Cazals-Hatem D, Pham BN, Gervais A, Le Breton V, et al. Prospective study on antihepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 2001;34:1000-5.
15. Dhumeaux D, Marcellin P, Lerebours E. Treatment of hepatitis C. The 2002 French consensus. Gut 2003;52:1784-7.
16. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with IFN-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
17. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Inter Med 2004;140:346-55.
18. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-a therapy. Ann Inter Med 1997;127:875-81.
19. Maylin S, Martinot-Peignoux M, Boyer N, Ripault MP, Féray C, Nicolas-Chanoine MH, et al. Evidence for eradication of HCV, assessed with transcription mediated amplification (TMA), in chronic hepatitis C patients with sustained virological response to therapy. J Hepatol 2006;44:S221.
20. Cadranel JF, Boujenah JL, Bourlière M, Fontanges T, Pol S, Trépo C, et al. Satisfaction of patients treated for chronic hepatitis C with the peginterferon alfa-2b pen device: the VISA observational study. Gastroenterol Clin Biol 2007;31:180-4.
21. Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006;131:1040-8.
22. Cacoub P, Ouzan D, Melin P, Lang JP, Rotily M, Fontanges T, et al. A prospective multicenter, observational study on compliance with viral hepatitis C treatments (CHEOBS study). Hepatology 2006;44:339.
23. Halfon P, Bourlière M, Penaranda G, Khiri H, Ouzan D. Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection. J Clin Microbiol 2006;44:2507-11.
24. Ouzan D. Comment obtenir une efficacité maximale du traitement actuel de l'hépatite chronique virale C ? Gastroenterol Clin Biol 2007;31:573-7.
25. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17.
26. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, Shafran SD, Barange K, Lin A, Soman A, Zeuzem S for the accelerate investigators. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. NEJM 2007;357:124-34.
27. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103.
28. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1:comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-97.
29. Pol S, Bourlière M. Optimizing treatment outcomes in chronic hepatitis C: management of non-response. Antivir Ther 2006;11:955-70.
30. Moucari R, Ripault MP, Oulès V, Martinot-Peignoux M, Asselah T, Boyer N, et al. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. J Hepatol 2007;46:596-604.
31. Benhamou Y, Pockros P, Rodriguez-Torres M, Gordon S, Shiffman M, Lurie Y, et al. The safety and efficacy of viramidine® plus pegylated interferon alpha-2b versus ribavirin plus pegylated interferon alpha-2b in therapy naive patients infected with HCV: phase 3 results. J Hepatol 2006;44:S273 (751).
32. Marcellin P, Lurie Y, Rodrigues-Torres M, Chasen R, Xu Y, Murphy B. The safety and efficacy of tarivaririn plus pegylated interferon alfa-2a versus ribavirin plus pegylated interferon alfa-2a in therapy naive patients infected with HCV:phase 3 results. J Hepatol 2007;46:S7 (10).
33. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110-3.
34. Neyts J. Selective inhibitors of hepatitis C virus replication. Antiviral Res 2006;71:363-71.
35. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science 2005;309:623-6.
36. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA. 2005;102:9294-9.
37. Pawlosky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007;132:1979-98.